Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Other Current Assets
Apontis Pharma AG
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Other Current Assets
€1.3m
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Other Current Assets
$4.1m
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Other Current Assets
€22m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
Merck KGaA
XETRA:MRK
|
Other Current Assets
€1.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
16%
|
CAGR 10-Years
0%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Other Current Assets
€27.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Other Current Assets
€2.5m
|
CAGR 3-Years
119%
|
CAGR 5-Years
79%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Other Current Assets?
Other Current Assets
1.3m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Other Current Assets amounts to 1.3m EUR.
What is Apontis Pharma AG's Other Current Assets growth rate?
Other Current Assets CAGR 3Y
45%
Over the last year, the Other Current Assets growth was 172%. The average annual Other Current Assets growth rates for Apontis Pharma AG have been 45% over the past three years .
You don't have any saved screeners yet